3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
Conditions
Breast Neoplasms
413
Carcinoma, Non-Small-Cell Lung
286
Prostatic Neoplasms
208
Neoplasms
204
Neoplasm Metastasis
180
Melanoma
164
Multiple Myeloma
158
Colorectal Neoplasms
158
Leukemia, Myeloid, Acute
143
Lung Neoplasms
132
Leukemia
126
Lymphoma
118
Pancreatic Neoplasms
117
Recurrence
111
Ovarian Neoplasms
111
Leukemia, Lymphocytic, Chronic, B-Cell
110
Lymphoma, Non-Hodgkin
105
Carcinoma, Renal Cell
104
Brain Neoplasms
90
Myelodysplastic Syndromes
88
Precursor Cell Lymphoblastic Leukemia-Lymphoma
86
Glioblastoma
85
Lymphoma, Large B-Cell, Diffuse
80
Lymphoma, Follicular
79
Carcinoma, Hepatocellular
79
Head and Neck Neoplasms
77
Squamous Cell Carcinoma of Head and Neck
76
Urinary Bladder Neoplasms
66
Stomach Neoplasms
61
Hodgkin Disease
60
Interventions
trifluridine tipiracil drug combination
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Terminated
×
High-grade Extra Pulmonary Neuroendocrine Cancer
×
Clear all
NCT04042714
2025-11-04
TAS-102 NEC
Baylor Research Institute
Phase 2
Terminated
14 enrolled